Agreement provides ProQR with initial payment of €12.5M and up to €135M in further payments, as well as potential additional earn outs based on commercial sales in the US and EU
Divestment of sepofarsen and ultevursen supports ProQR’s strategic focus on the Axiomer®&
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … scientific advisory board Dr. Yu’s research focuses on RNAediting and his expertise will help to develop the …
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas; initial pipeline targets to be disclosed in early 2023 with Analyst and Investor R&D event to be held in Q1 2023
Management Team appointments and p
… to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today … development and further advance our novel Axiomer ® RNAediting platform. With these events we look forward to …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNAediting technology platform, today announced the closing …
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … and ProQR’s RNA oligonucleotide platform and Axiomer RNAediting approaches. Event Details Date/Time: June 22, …
… to changing lives through the creation of transformative RNA medicines, today announced its “ProQR Vision 2023” … Further validate and expand ProQR's proprietary Axiomer ® RNAediting platform through first development candidate …
… opinion leaders and introduced next-generation Axiomer ® RNA technology platform. LEIDEN, the Netherlands, Aug. 16, … In May, three abstracts were presented on three of ProQR’s RNAediting approaches for inherited blindness at the Annual …